RheumNow Anniversary Perspective
Dr. Jack Cush provides a perspective on the first year anniversary of RheumNow.com - a site dedicated to delivering the wisdom, art and science of Rheumatology.
Blogs
KOLs Predict: What Will the Next Year Bring?
A new subspecialty may emerge. New drugs will be approved (but it will be difficult for patients to get coverage for them). And an American team will win the World Series. All these and more: here are predictions for 2017 and beyond from rheumatologists across the country and around the world.
RA Guidelines Shouldn't Ignore the Power of Methotrexate Combo Therapy
The introduction of the 2015 rheumatoid arthritis treatment guidelines has prompted discussion and critique from many. Here's my perspective on where monotherapy and methotrexate combination therapy fits in our armamentarium.
Writing Effective Appeal Letters
Getting the right drug to the right patient isn’t quite as easy as it should be. Here's a collection of appeal trench war musings and tactics with a sample letter for all to use.
Hydrocodone: Then and Now
Today marks the one year anniversary of hydrocodone becoming a schedule II drug with more restrictive access. Has life been better under these new rules?
Off-Label Use – A Free Speech, Scientific and Safety Issue
Is off-label drug use an example of "free speech"? Do off-label use guidelines affect every day practice or the way Pharma promotes its product outside of the indications for which it was approved?
Notes from the 2015 SPARTAN Meeting
Dr. Schwartzman reviews the proceedings of the 2015 Annual SPARTAN conference devoted to advances in spondyloarthritis.
Annual Review of Rheumatology Advances - 2014
This retrospective highlights several of the most impactful publications, trends, research and news that occurred in 2014.